Epoch Investment Partners Inc. Buys 2,430 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Epoch Investment Partners Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,436,042 shares of the biopharmaceutical company’s stock after acquiring an additional 2,430 shares during the quarter. Epoch Investment Partners Inc. owned approximately 1.13% of Halozyme Therapeutics worth $75,191,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HALO. TD Asset Management Inc raised its holdings in Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the last quarter. Congress Asset Management Co. MA raised its holdings in Halozyme Therapeutics by 16.2% in the 1st quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock valued at $16,592,000 after buying an additional 56,791 shares during the last quarter. Boston Trust Walden Corp bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $23,211,000. Los Angeles Capital Management LLC raised its holdings in Halozyme Therapeutics by 17.2% in the 1st quarter. Los Angeles Capital Management LLC now owns 121,000 shares of the biopharmaceutical company’s stock valued at $4,922,000 after buying an additional 17,716 shares during the last quarter. Finally, Norden Group LLC raised its holdings in Halozyme Therapeutics by 1,817.3% in the 1st quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock valued at $6,805,000 after buying an additional 158,559 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $59.24 on Friday. The company has a market cap of $7.54 billion, a price-to-earnings ratio of 24.48, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 52 week low of $32.83 and a 52 week high of $65.53. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The firm has a 50 day moving average of $58.40 and a 200-day moving average of $49.20.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total transaction of $551,200.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $9,269,861.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 84,881 shares of company stock valued at $4,888,184. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

HALO has been the subject of a number of research reports. TD Cowen raised their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group raised their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, September 13th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the company from $48.00 to $51.00 in a research report on Friday, June 7th. Finally, Benchmark reissued a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $60.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.